What is Pharmasol?
Pharmasol operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering a comprehensive suite of scalable services tailored for global personal care and pharmaceutical companies. Established in 1973, the company specializes in topical and oral applications, demonstrating proficiency in both aerosol and non-aerosol product formulations, including liquids, lotions, and gels. Its expansive 142,000 sq ft cGMP facilities are engineered for peak efficiency, safety, and adherence to stringent regulatory standards. Strategically situated near Boston's prominent academic and technological hubs, Pharmasol is adept at addressing complex client challenges in product development and manufacturing.
How much funding has Pharmasol raised?
Pharmasol has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in Pharmasol
PPP
Public-Private Partnership
What's next for Pharmasol?
The recent major strategic investment signals Pharmasol's readiness for accelerated expansion and enhanced service offerings. This capital infusion is likely to fuel advancements in manufacturing capabilities, research and development initiatives, and potentially broaden its market reach. As an established player in the CDMO space, Pharmasol is poised to leverage this financial impetus to solidify its position and capitalize on emerging opportunities within the pharmaceutical and personal care industries, driving innovation and operational excellence.
See full Pharmasol company page
